Thioguanine

Thioguanine

SCHEMBL4453632

NC(O)[C@H]1OC[C@H](O)[C@@H]1O.Nc1nc(S)c2[nH]cnc2n1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

IMPDH1IMPDH2

The experimentally established mechanism targets of Thioguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.39
GDA Q9Y2T3 1/20 0.39
CDK2 P24941 11/20 0.37
DPP4 P27487 1/20 0.37
CDK1 P06493 10/20 0.36
CCNB1 P14635 10/20 0.36
CCNA2 P20248 10/20 0.36
CCNA1 P78396 10/20 0.36
MGMT P16455 3/20 0.36
MAP3K5 Q99683 2/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
CCNB2 O95067 1/20 0.34
MAPK3 P27361 1/20 0.34
CLK1 P49759 1/20 0.34
CDK5 Q00535 1/20 0.34
PIN1 Q13526 1/20 0.34
CCNB3 Q8WWL7 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4456222 0.88 XDH (0.34) DPP4
SCHEMBL4453574 0.88
SCHEMBL4452455 0.87 MGMT (0.40) PDPK1GDACDK2DPP4CDK1
Mercaptopurine Anhydrous SCHEMBL4451627 0.84 LMNA (0.36) PDPK1CYP1A2
SCHEMBL4453628 0.84 MAP3K5 (0.58) PDPK1GDACDK2DPP4CDK1
SCHEMBL4459869 0.77 XDH (0.37) DPP4
SCHEMBL4456886 0.77
SCHEMBL4457015 0.75 LMNA (0.36) PDPK1CDK2HRH4CYP1A2
SCHEMBL4457972 0.74 MAP3K5 (0.43) MAP3K5CYP1A2
Thioguanine SCHEMBL183648 0.74 PDPK1 (0.66) PDPK1GDACDK2DPP4CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844063-A4 PURINE NUCLEOSIDE ANALOGS UTI LIMITED PARTNERSHIP (CA) 2009-06-17 EP claimed
US-20080070860-A1 Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside UTI LIMITED PARTNERSHIP (CA) 2008-03-20 US claimed
EP-1844063-A1 PURINE NUCLEOSIDE ANALOGS Uti Limited Partnership (CA) 2007-10-17 EP claimed
WO-2006081665-A1 PURINE NUCLEOSIDE ANALOGS UTI LIMITED PARTNERSHIP (CA) 2006-08-10 WO claimed
EP-1844063-A4 PURINE NUCLEOSIDE ANALOGS UTI LIMITED PARTNERSHIP (CA) 2009-06-17 EP disclosed
US-20080070860-A1 Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside UTI LIMITED PARTNERSHIP (CA) 2008-03-20 US disclosed
EP-1844063-A1 PURINE NUCLEOSIDE ANALOGS Uti Limited Partnership (CA) 2007-10-17 EP disclosed
WO-2006081665-A1 PURINE NUCLEOSIDE ANALOGS UTI LIMITED PARTNERSHIP (CA) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070860-A1 Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside PNP, MTAP, TYMP PDPK1 610/4885GDA 43/4885CDK2 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.